Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response

Experimental Neurology

Volumn 224, Issue 1, 2010, Pages 197-206

  Wang, David B ^a   Dayton, Robert D ^a   Zweig, Richard M ^b   Klein, Ronald L ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Adeno associated virus; Gene transfer; Gliosis; Immune response; Microarray; Microtubule associated protein tau; Neurodegenerative diseases; Progressive supranuclear palsy

Indexed keywords

CHEMOKINE; DOPAMINE; INTERFERON; MESSENGER RNA; PARVOVIRUS VECTOR; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DNA MICROARRAY; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; HISTOPATHOLOGY; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; MALE; MICROGLIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; CELL COUNT; GENE EXPRESSION PROFILING; GENE TRANSFER TECHNIQUES; GLIOSIS; INFLAMMATION; MALE; NEUROFIBRILLARY TANGLES; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTANTIA NIGRA; TAU PROTEINS;

EID: 77953709660     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.03.011     Document Type: Article

References (36)

1. Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33:95-130.
2. Cardozo C., Michaud C. Proteasome-mediated degradation of tau proteins occurs independently of the chemotrypsin-like activity by a nonprocessive pathway. Arch. Biochem. Biophys. 2002, 408:103-110.
3. Chen F., Wollmer M.A., Hoerndli F., Münch G., Kuhla B., Rogaev E.I., Tsolaki M., Papassotiropoulos A., Götz J. Role of glyoxalase I in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7687-7692.
4. Delobel P., Lavenir I., Ghetti B., Holzer M., Goedert M. Cell cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. Am. J. Pathol. 2006, 168:878-887.
5. Di Maria E., Tabaton M., Vigo T., Abbruzzese G., Bellone E., Donati C., Frasson E., Marchese R., Montagna P., Munoz D.G., Pramstaller P.P., Zanusso G., Ajmar F., Mandich P. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann. Neurol. 2000, 47:374-377.
6. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 2002, 168:3195-3204.
7. Ettinger R.A., Moustakas A.K., Lobaton S.D. Open reading frame sequencing and structure-based alignment of polypeptides encoded by RT1-Bb, RT1-Ba, RT1-Db, and RT1-Da alleles. Immunogenetics 2004, 56:585-596.
8. Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Mol. Neurodegener. 2009, 4:13.
9. Golde T.E. Disease modifying therapy for AD?. J. Neurochem. 2006, 99:689-707.
10. Gorlovoy P., Larionov S., Pham T.T., Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 2009, 23:2502-2513.
11. Ho L., Xiang Z., Mukherjee P., Zhang W., De Jesus N., Mirjany M., Yemul S., Pasinetti G.M. Gene expression profiling of the tau mutant (P301L) transgenic mouse brain. Neurosci. Lett. 2001, 310:1-4.
12. Hochrainer K., Mayer H., Baranyi U., Binder B., Lipp J., Kroismayr R. The human HERC family of ubiquitin ligases: novel members, genomic organization, expression profiling, and evolutionary aspects. Genomics 2005, 85:153-164.
13. Ishizawa K., Lin W.L., Tiseo P., Honer W.G., Davies P., Dickson D.W. A qualitative and quantitative study of grumose degeneration in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 2000, 59:513-524.
14. Janelsins M.C., Mastrangelo M.A., Park K.M., Sudol K.L., Narrow W.C., Oddo S., LaFerla F.M., Callahan L.M., Federoff H.J., Bowers W.J. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am. J. Pathol. 2008, 173:1768-1782.
15. Klein R.L., Dayton R.D., Lin W.L., Dickson D.W. Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. Neurobiol. Dis. 2005, 20:64-73.
16. Klein R.L., Dayton R.D., Tatom J.B., Diaczynsky C.G., Salvatore M.F. Tau expression levels from various adeno-associated virus serotypes produce graded neurodegenerative disease states. Eur. J. Neurosci. 2008, 27:1615-1625.
17. Klein R.L., Dayton R.D., Diaczynsky C.G., Wang D.B. Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer. Neurobiol. Aging 2009, (Electronic publication ahead of print).
18. Kumar-Singh S., Van Broeckhoven C. Frontotemporal lobar degeneration: current concepts in the light of recent advances. Brain Pathol. 2007, 17:104-114.
19. Lee H.G., Casadesus G., Zhu X., Castellani R.J., McShea A., Perry G., Peterson R.B., Bajic V., Smith M.A. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem. Int. 2009, 54:84-88.
20. Ludolph A.C., Kassubek J., Landwehrmeyer B.G., Mandelkow E., Mandelkow E.M., Burn D.J., Caparros-Lefebvre D., Frey K.A., de Yebenes J.G., Gasser T., Heutink P., Höglinger G., Jamrozik Z., Jellinger K.A., Kazantsev A., Kretzschmar H., Lang A.E., Litvan I., Lucas J.J., McGeer P.L., Melquist S., Oertel W., Otto M., Paviour D., Reum T., Saint-Raymond A., Steele J.C., Tolnay M., Tumani H., van Swieten J.C., Vanier M.T., Vonsattel J.P., Wagner S., Wszolek Z.K. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol. 2009, 16:297-309. Reisensburg Working Group for Tauopathies With Parkinsonism.
21. Martynoga B., Morrison H., Price D.J., Mason J.O. Foxg1 is required for specification of ventral telencephalon and region-specific regulation of dorsal telencephalic precursor proliferation and apoptosis. Dev. Biol. 2005, 283:113-127.
22. Mandelkow E., Song Y.H., Schweers O., Marx A., Mandelkow E.M. On the structure of microtubules, tau, and paired helical filaments. Neurobiol. Aging 1995, 16:347-354.
23. Mirra S.S., Murrell J.R., Gearing M., Spillantini M.G., Goedert M., Crowther R.A., Levey A.I., Jones R., Green J., Shoffner J.M., Wainer B.H., Schmidt M.L., Trojanowski J.Q., Ghetti B. Tau pathology in a family with dementia and a P301L mutation in tau. J. Neuropathol. Exp. Neurol. 1999, 58:335-345.
24. Mishto M., Bellavista E., Santoro A., Stolzing A., Ligorio C., Nacmias B., Spazzafumo L., Chiappelli M., Licastro F., Sorbi S., Pession A., Ohm T., Grune T., Franceschi C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol. Aging 2006, 27:54-66.
25. Noble W., Garwood C., Stephenson J., Kinsey A.M., Hanger D.P., Anderton B.H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 2009, 23:739-750.
26. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:363-373.
27. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego.
28. Poorkaj P., Muma N.A., Zhukareva V., Cochran E.J., Shannon K.M., Hurtig H., Koller W.C., Bird T.D., Trojanowski J.Q., Lee V.M., Schellenberg G.D. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann. Neurol. 2002, 52:511-516.
29. Rolstad B., Vaage J.T., Naper C., Lambracht D., Wonigeit K., Joly E., Butcher G.W. Positive and negative MHC class I recognition by rat NK cells. Immunol. Rev. 1997, 155:91-104.
30. Sahara N., Maeda S., Yoshiike Y., Mizoroki T., Yamashita S., Murayama M., Park J.M., Saito Y., Murayama S., Takashima A. Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain. J. Neurosci. Res. 2007, 85:3098-3108.
31. Schneider J.A., Bienias J.L., Gilley D.W., Kvarnberg D.E., Mufson E.J., Bennett D.A. Improved detection of substantia nigra pathology in Alzheimer's disease. J. Histochem. Cytochem. 2002, 50:99-106.
32. Shimura H., Miura-Shimura Y., Kosik K.S. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J. Biol. Chem. 2004, 279:17957-17962.
33. Song D.Y., Yang Y.C., Shin D.H., Sugama S., Kim Y.S., Lee B.H., Joh T.H., Cho B.P. Axotomy-induced dopaminergic neurodegeneration is accompanied with c-Jun phosphorylation and activation transcription factor 3 expression. Exp. Neurol. 2008, 209:268-278.
34. Wakabayashi K., Oyanagi K., Makifuchi T., Ikuta F., Homma A., Homma Y., Horikawa Y., Tokiguchi S. Corticobasal degeneration: etiopathological significance of the cytoskeletal alterations. Acta Neuropathol. 1994, 87:545-553.
35. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski T.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
36. Zilka N., Stozicka Z., Kovac A., Pilipcinec E., Bugos O., Novak M. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J. Neuroimmunol. 2009, 209:16-25.